Literature DB >> 28534080

Pathologic Complete Response Rates After Neoadjuvant Treatment in Rectal Cancer: An Analysis of the National Cancer Database.

Patrick D Lorimer1, Benjamin M Motz1, Russell C Kirks1, Danielle M Boselli2, Kendall K Walsh1, Roshan S Prabhu3, Joshua S Hill1, Jonathan C Salo4.   

Abstract

BACKGROUND: Pathologic complete response (pCR) of rectal cancer following neoadjuvant therapy is associated with decreased local recurrence and increased overall survival. This study utilizes a national dataset to identify predictors of pCR in patients with rectal cancer.
METHODS: The National Cancer Database was queried for patients with nonmetastatic rectal cancer (2004-2014) who underwent neoadjuvant therapy and surgical resection. Unadjusted associations were assessed using rank-sum tests and χ 2 tests where appropriate. Backward elimination and forward selection multivariable logistic regression models were created to determine the relationship of annual surgical volume with pCR rate, adjusting for preoperative characteristics and radiation-surgery interval. Statistical tests were two-sided, with a significance level of p ≤ 0.05. Analyses were performed using SAS version 9.4.
RESULTS: A total of 27,532 patients from 1179 participating hospitals met the inclusion criteria. Generalized linear mixed models demonstrated that the odds of achieving pCR was independently associated with more recent diagnosis, female sex, private insurance, lower grade, lower clinical T classification, lower clinical N classification, increasing interval between the end of radiation and surgery, and treatment at higher-volume institutions.
CONCLUSIONS: pCR was associated with favorable tumor factors, insurance status, time between radiation and surgery, and institutional volume. It is not clear what is driving the higher rates of pCR at high-volume institutions. Research targeted at understanding processes that are associated with pCR in high-volume institutions is needed so that similar results can be achieved across the spectrum of facilities caring for patients in this population.

Entities:  

Mesh:

Year:  2017        PMID: 28534080     DOI: 10.1245/s10434-017-5873-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.

Authors:  Oliver S Chow; Sujata Patil; Metin Keskin; J Joshua Smith; Maria Widmar; David D Smith; Karin Avila; Jinru Shia; Peiguo Chu; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2019-02-04       Impact factor: 3.452

2.  Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.

Authors:  Ali Yaghobi Joybari; Payam Azadeh; Siamak Babaei; Farnaz Hosseini Kamal
Journal:  Pathol Oncol Res       Date:  2019-02-02       Impact factor: 3.201

3.  The split scar sign as an indicator of sustained complete response after neoadjuvant therapy in rectal cancer.

Authors:  Inês Santiago; Maria Barata; Nuno Figueiredo; Oriol Parés; Vanessa Henriques; António Galzerano; Carlos Carvalho; Celso Matos; Richard J Heald
Journal:  Eur Radiol       Date:  2019-07-26       Impact factor: 5.315

4.  The Role of Adjuvant Chemotherapy in ypT0N0 Rectal Adenocarcinoma.

Authors:  Anita Nguyen; David R James; Eric J Dozois; Scott R Kelley; Kellie L Mathis
Journal:  J Gastrointest Surg       Date:  2019-02-06       Impact factor: 3.452

5.  Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Zhongxu Zhu; Xin Wang; Ane Etxart; Yangsoon Park; Luis Bujanda; In Ja Park; Ajay Goel
Journal:  JCO Precis Oncol       Date:  2021-12-02

6.  A comparative analysis of the clinicopathological profile of early-onset versus late-onset rectal cancer patients.

Authors:  Vinita Trivedi; Richa Chauhan; Santosh Subham; Rita Rani; Usha Singh
Journal:  Ecancermedicalscience       Date:  2022-03-14

7.  Provider Viewpoints in the Management and Referral of Rectal Cancer.

Authors:  Xiang Gao; Kristin S Weeks; Irena Gribovskaja-Rupp; Imran Hassan; Marcia M Ward; Mary E Charlton
Journal:  J Surg Res       Date:  2020-10-10       Impact factor: 2.192

8.  Neoadjuvant radiation above NCCN guidelines for rectal cancer is associated with age under 50 and early clinical stage.

Authors:  Jonathan T Bliggenstorfer; Katherine Bingmer; Asya Ofshteyn; Sharon L Stein; Ronald Charles; Emily Steinhagen
Journal:  Surg Endosc       Date:  2021-06-10       Impact factor: 4.584

9.  Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.

Authors:  Zhuokai Zhuang; Zongchao Liu; Juan Li; Xiaolin Wang; Peiyi Xie; Fei Xiong; Jiancong Hu; Xiaochun Meng; Meijin Huang; Yanhong Deng; Ping Lan; Huichuan Yu; Yanxin Luo
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

10.  Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells.

Authors:  Xiaofei Li; Ruifang Tian; Lan Liu; Lihui Wang; Dong He; Ke Cao; John K Ma; Chenghui Huang
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.